- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03669952
Study of the Influence of Ductal Carcinoma in Situ on the Outcome of Invasive Breast Cancer
Longitudinal Observational Study About the Influence of Ductal Carcinoma in Situ on the Outcome of Invasive Breast Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Type of study:
A prospective observational longitudinal study was performed on patients who had undergone curative surgery for primary invasive breast cancer between 2010 and 2015. The study was performed in a single breast pathology unit [Alt Penedés hospital and Sant Camil hospital(GAP)]. Only patients with a definitive histopathology-based diagnostic of ductal carcinoma were included. Patients diagnosed with metastasis were excluded. Patients with bilateral breast cancer were included as two independent study cases.
Patients:
Sample size calculation: 191. A total of 464 patients were included in the study. IDC was present in 221 patients (47.6%) and IDC + DCIS was present in 243 patients (52.4%).
Data collected included clinical characteristics (age, laterality and clinical symptoms at the time of diagnostic), histopathological information (tumor size, tumor grade, hormone receptors, nodal status, HER-2 mutation (erb-b2 receptor tyrosine kinase 2), number of ki67, presence and percentage of DCIS, grade of DCIS, and surrogate subtype) and surgical procedure performed.
Tumor histopathology and the number of lymph nodes involved were evaluated by routine hematoxylin-eosin (H&E) staining. The histological response to chemotherapy was assessed according to Miller-Payne criteria of grading (MPG) and Residual Disease in Breast and Nodes (RDBN).
The percentage of DCIS and its grade (classified as low, intermediate or high) was measured by two independent pathologists.
Statistical analysis:
Quantitative data are shown as the median or mean of values and their variability is expressed as the range or standard deviation (SD), as specified for each analysis. Qualitative data are shown as absolute values or percentages. The incidence was used as a measure of frequency and the relative risk as a measure of association between independent groups.
The study of the normality of quantitative variables was done applying the Kolmogorov-Smirnov or the Shapiro-Wilk tests, as indicated for each analysis. For significance assessment of quantitative data, unpaired Student's T-test or two-tailed Mann-Whitney U test was applied, as specified for each analysis. For significance assessment of qualitative data, Fisher's exact test or Chi-squared test was applied. For the analysis of more than two groups, one-way ANOVA and Tukey's range test for post hoc pairwise comparison of groups, or Kruskal-Wallis were used. Survival was analyzed with the Kaplan-Meier estimate and survival distributions compared with the Log-Rank test. Multivariate Cox proportional hazards regression model was used to simultaneously evaluate the effect of several factors on survival and mortality.
Statistical analysis was performed using the software SPSS® (Statistical Package for the Social Sciences) version 21.
The aim of the investigator's study is to compare the clinical and histopathological factors between patients with IDC or DCIS-associated IDC (IDC + DCIS) and find the prognostic factors associated to recurrence and mortality in each group.
Study Type
Enrollment (Actual)
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients with invasive ductal carcinoma of the breast
- Patients who received surgery for primary invasive breast cancer between 2010 and 2015
Exclusion Criteria:
- Patients with metastasis at the diagnostic
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Invasive ductal carcinoma
Patients with Invasive ductal carcinoma
|
No interventions are realized, only observational study
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Recurrence
Time Frame: Patients included between 2010 and 2015 will be follow up til January of 2018 with a mean follow up of 51.43 months
|
Neoplasm metastasis, either local or distant recurrence of the invasive ductal carcinoma
|
Patients included between 2010 and 2015 will be follow up til January of 2018 with a mean follow up of 51.43 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Adenocarcinoma
- Neoplasms, Glandular and Epithelial
- Breast Diseases
- Neoplasms, Ductal, Lobular, and Medullary
- Breast Carcinoma In Situ
- Carcinoma in Situ
- Breast Neoplasms
- Carcinoma
- Carcinoma, Ductal
- Carcinoma, Intraductal, Noninfiltrating
Other Study ID Numbers
- SLG_01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Outcome of Breast Cancer
-
Shandong Cancer Hospital and InstituteNot yet recruitingBreast Cancer Female | Patient Reported Outcome | Breast-conserving Surgery | Oncological Safety
-
OnkoZentrum Zürich AGUniversity of Zurich; Palleos Healthcare GmbHCompletedHER2-positive Breast Cancer | Biosimilar | Patient Reported OutcomeSwitzerland
-
Lund UniversityRegion SkaneCompleted
-
Fudan UniversityThe First Affiliated Hospital with Nanjing Medical University; First People... and other collaboratorsRecruitingBreast Cancer | Breast Reconstruction | Patient Reported Outcome Measures | Oncoplastic Breast-conserving SurgeryChina
-
Ganin Fertility CenterThe Cleveland Clinic; University of the Western CapeCompletedGender Ratio of ICSI OutcomeEgypt
-
Tribhuvan University Teaching Hospital, Institute...CompletedFOCUS of Study: Time of Admission to ICU and OutcomeNepal
-
Methodist Health SystemRecruitingClinical Outcome of Pericardial Closure Using GentrixUnited States
-
Nuvation Bio Inc.WithdrawnBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Breast Carcinoma | Cancer of Breast | Malignant Tumor of Breast | Breast Tumor | Cancer of the BreastUnited States
-
Medical University of ViennaUnknownQuality of Life | Morbidity | Breast Image Scale Index for Self Esteem Evaluation | Breast Symmetry Index | Oncological OutcomeAustria
-
Cairo UniversityUnknown
Clinical Trials on None intervention
-
University of Campania "Luigi Vanvitelli"RecruitingBirth Weight | Systemic Inflammation Markers | Combined Systemic Inflammatory IndicesItaly
-
University of GiessenCompleted
-
Peking University First HospitalActive, not recruitingSARS-CoV-2 Infection | Hematologic MalignancyChina
-
Acibadem UniversityCompleted
-
Acibadem UniversityCompleted
-
Universidad Católica del MauleFondo Nacional de Desarrollo Científico y Tecnológico, ChileCompletedMental Disorders | Suicide, AttemptedChile
-
Shanghai Mental Health CenterUnknownSchizophrenia | ViolenceChina
-
Sir Run Run Shaw HospitalCompleted
-
Sir Run Run Shaw HospitalUnknown
-
Azienda Ospedaliero Universitaria Maggiore della...CompletedChronic Kidney Diseases